- Five-Year Business Highlights
- Quarter Business Highlights
Principal Financial Data
| Fiscal year (millions of yen) |
ending March 2021/Q1 | ending March 2021/Q1～2 | ending March 2021/Q1～3 | ending March 2021/Q1～4 | ending March 2022/Q1 | ending March 2022/Q1～2 | ending March 2022/Year Ended (forecast) | ||
|---|---|---|---|---|---|---|---|---|---|
| Net sales | 29,913 | 57,817 | 91,837 | 121,885 | 41,157 | 71,568 | 135,000 | ||
| Pharmaceuticals | 26,209 | 50,296 | 80,243 | 106,478 | 37,050 | 63,430 | 119,300 | ||
| Functional food | 3,703 | 7,521 | 11,594 | 15,406 | 4,106 | 8,138 | 15,700 | ||
| Operating income | 7,522 | 11,140 | 20,362 | 26,134 | 16,448 | 21,504 | 28,000 | ||
| Ordinary income | 7,723 | 11,248 | 21,023 | 26,760 | 16,598 | 22,250 | 28,500 | ||
| Net income attributable to owners of the parent | 5,835 | 8,073 | 15,085 | 20,702 | 12,341 | 16,561 | 21,000 | ||
| Depreciation and amortization | ― | 1,740 | ― | 3,550 | ― | 1,453 | 3,800 | ||
| Capital investment | ― | 999 | ― | 2,583 | ― | 1,102 | 4,800 | ||
| R&D expenses | 2,836 | 7,659 | 11,459 | 16,104 | 3,699 | 10,005 | 26,500 | ||
| Total assets | 178,391 | 180,453 | 181,840 | 197,028 | 200,114 | 204,052 | |||
| Net assets | 149,763 | 152,621 | 156,256 | 162,543 | 170,465 | 174,890 |
Net Sales
For 1Q and 2Q of the fiscal year ending March 2022, net sales were 71,568 million yen, an increase of 23.8% from the same quarters of the previous fiscal year. The factors behind the result include sales of Vidaza, a treatment for myelodysplastic syndromes and acute myeloid leukemia (AML), and Uptravi, a treatment for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), and royalty income from overseas sales of these products, as well as income from the sale of priority review vouchers issued by the U.S. Food and Drug Administration (FDA).
Operating income
Net income attributable to owners of the parent
Operating income was 21,504 million yen, a 93.0% increase from 1Q and 2Q of the previous fiscal year, and net income attributable to owners of the parent was 16,561 million yen, a 105.1% increase. The factors behind the results include a decrease in the ratio of cost to sales caused by the increase in sales and improvement of the sales mix.
R&D expenses
Cash Flows
| Fiscal year (millions of yen) |
ending March 2021/Q1 | ending March 2021/Q1～2 | ending March 2021/Q1～3 | ending March 2021/Q1～4 | ending March 2022/Q1 | ending March 2022/Q1～2 |
|---|---|---|---|---|---|---|
| Cash flow from operating activities | ― | 8,127 | ― | 21,388 | ― | 13,333 |
| Cash flow from investing activities | ― | -2,071 | ― | -1,564 | ― | -1,954 |
| Cash flow from financing activities | ― | -2,899 | ― | -6,199 | ― | -3,365 |
Long-term Chronological Data
View long-term chronological data from here.